PRE-CONFERENCE WORKSHOP DAY

 

Join the Pre-Conference Day on Monday the 7th of September and be part of an interactive day of learning, networking and innovation hearing from industry leaders.


In 2019 our workshops included The Gene Editing Summit with Dr Danilo Maddalo, Laboratory Head, Novartis Institutes for Biomedical Research, AI in Healthcare Summit featuring Dr Barry Rosen, Senior Principal Scientist/Director, AstraZeneca and Cord Blood Workshops with Chris Leonforte, Processing and QC Manager, Anthony Nolan. You can book your ticket here.

 

 

ADVANCED THERAPIES WORKSHOPS & SUMMITS

  • Gene therapy for rare disease summit
  • Gene editing summit
  • C-Level board room meeting
  • Regulation, reimbursement and market access workshop

MANUFACTURE & BIOPROCESSING WORKSHOPS & SUMMITS

  • Bioprocessing Workshop
  • Cell Therapy Workshop
  • End-to-end logistics and supply chain workshop
  • Automated Bioprocessing


CORD BLOOD WORKSHOPS
 

  • Cord blood regulation
  • Cord blood expansion
  • Sustainability
     

 

PLENARY, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

14:45

Afternoon Networking Break

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

BIOPROCESS, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

WORKSHOP A - BIOPROCESS

Towards CellTherapy4.0 self-adaptive and self-managed manufacturing pipelines

Jan Schrooten
BIOPROCESS
13:50

Turn cells into therapies by end-to-end innovation strategies

  • Enable personalized ATMP manufacturing
  • Quality-by-design based ATMP processes development
  • Digital ATMP factory
14:45

Afternoon Networking Break

WORKSHOP A - BIOPROCESS

Manufacture & Bioprocess of Gene Modified Cell Therapies

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

LOGISTICS/DELIVERY TO PATIENT, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

LOGISTICS/DELIVERY TO PATIENT
13:00

Tech transfer forum: tools, tactics, strategies and approaches

As the cell therapy manufacturing sector matures, novel directions regarding its outlook in the coming decade should be explored.Automated manufacturing process units are increasingly being adopted by product developers and/or CMOs allowing for the gradual build-up of real-time data sets. This will gradually result in whole-bioprocesses that could eventually operate in a semi-autonomous and self-adaptive manner. Given the, flexibility, agility of future manufacturing schemes in low footprint equipment and potentially personalised processes, the question of whether we reach a point where real-time release can become a reality remains to be answered.
  • Flirting with the control aspects, machine learning and AI tools and linking these to the actual process
  • From mechanistic exploration to data-driven implementation
  • High throughput Analytics for Cell Therapy Process Optimization
  • Producing high volumes of high-quality data for ‘era of 4.0 industry’ and ‘smart bioprocessing’ without good data, which we currently don’t have a lot of.
  • Data acquisition and structuring: useful while building clinical portfolio
15:00

Afternoon Networking Break

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 10/Feb/20 09:25

GENE EDITING, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

14:45

Afternoon Networking Break

WORKSHOP E - GENE EDITING/IMMUNOTHERAPY

Chair: Hansjörg Hauser, Head of Department Gene Regulation and Differentiation, Helmholtz Centre for Infection Research

Todd C Mcdevitt
GENE EDITING
15:15

Tackling the challenge of cell quality in large scale genome wide CRISPR screening for drug discovery

Lise Marie Grav
GENE EDITING
15:40

CRISPR-mediated genome engineering of CHO cell lines for production of therapeutic proteins

Dr Barry Rosen
GENE EDITING
16:05

TBC Precise genome engineering to empower drug discovery

Andrew Sewell
GENE EDITING
16:30

SPECIAL SESSION: IMMUNOTHERAPY Learning from immunotherapy successes with solid tumours

Andrew Sewell, Professor, Infection And Immunity, Cardiff University
Luis Borges
GENE EDITING
17:10

Genetically engineered iPSC-derived immune cells for cancer immunotherapy

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

STANDARDS DEVELOPMENT, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

WORKSHOP B - STANDARDS DEVELOPMENT

Chair: Dawn Henke, Senior Technical Program Manager, Standards Coordinating Body

Dawn Henke
STANDARDS DEVELOPMENT
13:00

Standards for Advanced Therapies

  • Discussing the current landscape of standards applicable to advanced therapies and standards under development
  • Discussion of needed standards for advanced therapies
  • How to be involved in developing advanced therapies standards and the Standards Coordinating Body
Elsa Abranches
STANDARDS DEVELOPMENT
13:25

Title TBC (STANDARDS DEVELOPMENT)

Jim Richardson
STANDARDS DEVELOPMENT
13:50

USP Standards for Cell and Gene Therapies

  • Existing applicable USP standards relevant to Cell and Gene Therapies
  • Standards in Development
  • Other needed standards and future development
Marc Turner
STANDARDS DEVELOPMENT
14:15

Global Alliance on iPSC Therapies: challenges in developing international consensus standards

  • If cellular therapy products derived from induced pluripotent stem cell (iPSC) lines are to be available across international regulatory jurisdictions then a common set of criteria need to be agreed for defining what constitutes clinical grade lines.
  • Similarly, if different iPSC lines are used for manufacture of a single cellular therapy product, for example in the autologous or HLA-matched allogeneic context, then comparability will need to be demonstrable.
  • GAiT has been working with international partners to develop a consensus set of quality guidelines for clinical grade iPSC lines and standardise the assays which support them.
14:45

Afternoon Networking Break

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

IMMUNOTHERAPY (Workshop), Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

14:45

Afternoon Networking Break

WORKSHOP E - GENE EDITING/IMMUNOTHERAPY

Chair: Hansjörg Hauser, Head of Department Gene Regulation and Differentiation, Helmholtz Centre for Infection Research

Todd C Mcdevitt
IMMUNOTHERAPY (Workshop)
15:15

Tackling the challenge of cell quality in large scale genome wide CRISPR screening for drug discovery

Lise Marie Grav
IMMUNOTHERAPY (Workshop)
15:40

CRISPR-mediated genome engineering of CHO cell lines for production of therapeutic proteins

Dr Barry Rosen
IMMUNOTHERAPY (Workshop)
16:05

TBC Precise genome engineering to empower drug discovery

Andrew Sewell
IMMUNOTHERAPY (Workshop)
16:30

SPECIAL SESSION: IMMUNOTHERAPY Learning from immunotherapy successes with solid tumours

Andrew Sewell, Professor, Infection And Immunity, Cardiff University
Luis Borges
IMMUNOTHERAPY (Workshop)
17:10

Genetically engineered iPSC-derived immune cells for cancer immunotherapy

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

RARE DISEASE, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

WORKSHOP C - RARE DISEASE

Philip John Brooks
RARE DISEASE
13:00

Increasing efficiency in rare genetic disease therapeutics development: can alternate approaches from cancer research be adopted

Stefano Zancan
RARE DISEASE
13:25

The meaning of access to therapy for a patient with a rare disease, and how a clinical site should take into consideration this aspect

Stefano Zancan, Head Clinical Development And Operations, Fondazione Telethon
Fatima Sulaiman
RARE DISEASE
13:50

The role of patient organisations in precision medicine development

  • A new strategy for research into rare diseases and the roles that patient organisations play
  • The unmet need of precision medicine for scleroderma and other rare orphan conditions
  • Working together with industry to enable development and access to therapies
Fatima Sulaiman, Head Of Research And Services, Scleroderma and Raynaud's UK
Tara Britt
RARE DISEASE
14:15

Policy legislation and global reach for rare diseases

14:45

Afternoon Networking Break

WORKSHOP C - RARE DISEASE

Scientific advice and early dialogue to achieve clinical success and data collection later on

Panel discussion
RARE DISEASE
15:15

Patient Advocacy Groups and their Evolving & Unique Business Models

  • How the role of patient organizations is changing in the drug development process
  • A case study from the Charcot-Marie-Tooth Association in accelerating drug development for CMT
  • Access to preclinical testing services, key opinion leaders, and the patient community is changing the landscape of drug development in CMT
Panel discussion
17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

CORD BLOOD, Monday 30 March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

WORKSHOP D - CORD BLOOD

Chair: Moshe Israeli, Medical Director, Rabin Medical Center

Dr Joanne Kurtzberg
CORD BLOOD
13:00

Keynote: Novel cellular therapies derived from cord blood monocytes

  • Studies in children with selective inborn errors of metabolism have shown that cord blood cells, administered intravenously after myeloablative therapy, and engraft in the brain.
  • DUOC-01, a cord blood derived cellular therapy that promotes myelination, is undergoing testing to augment standard umbilical cord blood treatment in children with leukodystrophies.
  • These observations led us to hypothesize that cord blood cells might also have efficacy treating patients with acquired brain injuries.
Dr Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
John Wagner
CORD BLOOD
13:25

Cord blood as source marked for novel cellular therapeutics

Marcie Finney
CORD BLOOD
13:50

Diverse use of cord blood

André Gerth
CORD BLOOD
14:15

CartiCure – An ATMP based on mesenchymal stromal cells for orthopaedic

  • Best tissue for isolation of MSC from human tissue
  • Application of MSC for treatment of cartilage defect in knee
  • Preclinical and clinical trial
14:45

Afternoon Networking Break

WORKSHOP D - CORD BLOOD

Chair: Moshe Israeli, Medical Director, Rabin Medical Center

Mathias Svahn
CORD BLOOD
15:15

Clinical trials with mesenchymal stem cells from cord tissue, used for treatment of diabetes type-1

Jaime Shamonki
CORD BLOOD
15:40

Beyond Biostorage: How Cord Blood Banks Can Stay Relevant to Customers

  • How can cord blood banks best serve clients and clinicians as utility (perceived and real) of perinatal stem cells evolves
  • What is the role of personalized medicine and proactive health care in deciding to bank perinatal stem cells
  • What additional meaningful services can banks provide besides biostorage
Jaime Shamonki, Chief Medical Officer, CBR by Generate Life Sciences
Panel discussion
17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 04/Jun/20 09:25

“Many thanks for a great conference. It was a great event for networking and content.”

 

Programme Manager, EATRIS